Johnson & Johnson’s $3.5 Billion Prostate Cancer Drug Sales At Risk?

By Trefis Team, Contributor Johnson & Johnson (NYSE:JNJ) is the leader in the prostate cancer hormonal therapy market, with Zytiga sales of $3.5 billion in 2018. Other key drugs include Astellas’ Xtandi, and AbbVie’s Lupron. However, Zytiga could see a sharp decline in sales over the next few years, as it will face biosimil… …read more

Read more here::